Karyopharm KPT-IST-391 (Relapsed/Refractory Multiple Myeloma) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an experimental combination of drugs (selinexor, ruxolitinib, and methylprednisolone) is a safe and effective option for treating multiple myeloma that has come back after treatment or is not responding to treatment.
Relapsed/Refractory Multiple Myeloma
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with multiple myeloma that has 1 of the following features: clonal bone marrow plasma cells >10% or biopsy-proven bony or extramedullary plasmacytoma
- Did not have an adequate response to treatment that included the following drugs: anti-CD38 antibody, immunomodulatory agent, proteasome inhibitor
For more information, contact the study team at quinna.marshburn@duke.edu.
What is Involved?
Everyone who takes part in this study will receive the study drug regimen. No placebo is used in this study.
If you choose to join, you will:
- Take selinexor once per week
- Take ruxolitinib twice per day
- Take methylprednisolone every other day
Your progress will be assessed at the end of each 28-day period of taking the study regimen. These 28-day periods are called "cycles." The number of cycles you do in this study will depend on how you respond to the study drug regimen.
Study Details
